Table 2 Univariate statistical analysis comparing all gait parameters (mean ± SD) between PD and PSP patients.

From: Gait analysis may distinguish progressive supranuclear palsy and Parkinson disease since the earliest stages

Features

Measure

GAIT task

COG dual task

PD

PSP

Mean ± SD

p-value

PD

Mean ± SD

PSP

Mean ± SD

p-value

Cycle duration

s

1.10 ± 0.11

1.29 ± 0.23

< 0.0001***

1.16 ± 0.14

1.42 ± 0.28

< 0.0001***

Stance duration

s

0.67 ± 0.08

0.82 ± 0.16

< 0.0001***

0.72 ± 0.09

0.94 ± 0.22

< 0.0001***

Swing duration

s

0.37 ± 0.10

0.27 ± 0.08

< 0.0001***

0.26 ± 0.08

0.26 ± 0.05

0.221

Variability of swing duration

s

0.07 ± 0.06

0.17 ± 0.13

< 0.0001***

0.13 ± 0.04

0.16 ± 0.04

< 0.0001***

Stance phase

%

60.27 ± 1.97

62.84 ± 2.79

< 0.0001***

61.95 ± 2.20

65.64 ± 3.51

< 0.0001***

Swing phase

%

39.54 ± 1.70

37.01 ± 2.89

< 0.0001***

38.54 ± 3.62

34.36 ± 3.51

< 0.0001***

Single support phase

%

39.45 ± 2.12

37.05 ± 2.95

< 0.0001***

38.08 ± 2.54

34.36 ± 3.51

< 0.0001***

Double support phase

%

10.82 ± 2.95

15.05 ± 6.58

< 0.0001***

12.64 ± 3.10

17.47 ± 5.02

< 0.0001***

Mean velocity

m/s

1.04 ± 0.16

0.68 ± 0.26

< 0.0001***

0.89 ± 0.19

0.52 ± 0.23

< 0.0001***

Mean velocity

%height/s

62.07 ± 10.31

41.69 ± 15.00

< 0.0001***

53.58 ± 10.95

31.79 ± 13.53

< 0.0001***

Cadence^

Steps/min

109.61 ± 11.52

95.80 ± 17.27

0.002**

104.63 ± 12.30

87.99 ± 17.51

0.001**

Cycle length

m

1.13 ± 0.14

0.84 ± 0.21

< 0.0001***

1.02 ± 0.17

0.69 ± 0.22

< 0.0001***

Cycle length

%height

67.77 ± 8.82

51.70 ± 12.54

< 0.0001***

61.47 ± 10.79

42.59 ± 12.95

< 0.0001***

Step length

m

0.46 ± 0.15

0.25 ± 0.13

< 0.0001***

0.33 ± 0.10

0.24 ± 0.17

< 0.0001***

Variability of step length

m

0.27 ± 0.42

0.31 ± 0.51

0.105

0.24 ± 0.20

0.21 ± 0.30

< 0.0001***

Step width

m

0.10 ± 0.07

0.11 ± 0.04

0.156

0.11 ± 0.10

0.12 ± 0.06

0.088

  1. PD Parkinson’s disease, PSP progressive supranuclear palsy.
  2. **Significance level at 0.01.
  3. ***Significance level at 0.001.
  4. ^Normally distributed according to the Shapiro Wilk test (homoscedasticity verified for all t-tests) and t-test applied; the other data were analyzed with a Mann Whitney test.
Back to article page